PALM DESERT, CA, MAY 17, 2018 – ASC Biosciences, Inc. (“ASC”) symbol ASCW, is
pleased to announce that Paul Lucas Ph.D. will speak tomorrow at the World
Advanced Therapies & Regenerative Medicine Congress 2018, to be held at the
Business Design Center in London, United Kingdom on May 16 through May 18, 2018.
Dr. Lucas is Associate Professor of Orthopaedic Surgery at New York Medical College,
and the Scientific Founder of ASC.
Dr. Lucas will outline ASC’s potentially groundbreaking therapeutic treatments in the
field of orthopaedic and aesthetic surgery, made possible by the invention of our
patented Multipotent Adult Stem Cells (MASCs), He will also share the results of his
most recent research, involving inter-species transplantation of MASCs.
This research paves the way for offshore human trials in the coming months using
Dr. Lucas is currently scheduled to speak at 9:00 AM on Friday, May 18, 2018 in the
track on “New Frontiers in Repair & Replacement of Diseased Tissue and Organs”.
The full conference schedule can be viewed at the official congress web site:
About ASC Biosciences, Inc.
ASC Biosciences, Inc. (“ASC” or the “Company”) is a
development stage biotechnology company that has a proprietary adult stem cell
platform capable of forming nearly every tissue in the human body. These cells,
Multipotent Adult Stem Cells (“MASCs”), will differentiate into cartilage, bone, tendon,
muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have
apparent unlimited proliferation potential (do not reach replicative senescence) and
have been shown to regenerate tissues by differentiating into the cell types at the site.
MASCs lack the ability to cause a rejection response and can thus be used allogenically
– which means that cells harvested from a single donor can be expanded in culture and
the expanded cells can be used to treat hundreds, thousands, or millions of patients.
ASC believes it has a sustainable competitive advantage with its MASCs. Once FDA
approved, the Company’s MASCs will replace the need to use autologous stem cells for
therapies. The MASCs will essentially become known as “cells in a bottle”, providing a
specified dose of adult stem cells for specific therapies, which is an enormous
advantage over harvesting cells from a patient’s body. ASC intends to establish an
intellectual property portfolio that will provide proprietary dominion in the repair and
regeneration of all human tissues. For more information visit: http://www.ascbio.com or
@ASCbio1 on Facebook.
Certain statements contained herein constitute “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations, estimates and projections about ASC
Biosciences, Inc. industry, management’s beliefs and certain assumptions made by
management. Readers are cautioned that any such forward-looking statements are not
guarantees of future performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Because such statements involve risks and
uncertainties, the actual results and performance of the Company may differ materially
from the results expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such forwardlooking
statements. Unless otherwise required by law, the Company also disclaims any
obligation to update its view of any such risks or uncertainties or to announce publicly
the result of any revisions to the forward-looking statements made here. Readers
should review carefully reports or documents the Company files periodically with the
Contact: ASC Biosciences, Inc. Neville Pearson, President/Chief Executive Officer
Neville@ascbio.com or email@example.com.